Clinical Trials Logo
  1. Home
  2. Moderate to Severe Psoriasis
  3. NCT00256139

CLEAR Study: Clinical Experience Acquired With Raptiva Study

Moderate to Severe Psoriasis Clinical Trial

Clinical Trial Summary

A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered Raptiva in the treatment of patients with moderate to severe psoriasis

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00256139
Study type Interventional
Source Merck KGaA
Contact
Status Completed
Phase Phase 3
Start date March 2003
Completion date October 2004
View Details
See also
  Status Clinical Trial Phase
Completed NCT00678470 - Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis N/A
Terminated NCT01156532 - Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy N/A
Completed NCT00936065 - Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis Phase 4
Completed NCT00442650 - Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis Phase 3
Completed NCT05344248 - Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing Phase 1/Phase 2
Completed NCT03051217 - A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis Phase 2/Phase 3